Loading viewer...
investor_presentation
Format: PDF investor_presentation
Chr. Hansen presents its Q4 2019/20 roadshow covering market and technology leadership across human health, animal health, plant health, and live biotherapeutics segments. The presentation highlights the company's microbial platform revenue composition, with food cultures and enzymes representing 71% of continuing operations revenue and health and nutrition at 29% on a pro-forma basis including recent acquisitions.
investor_presentation
Baby Bunting
investor_presentation
Atento